依洛尤单抗联合阿托伐他汀钙治疗冠心病合并高血脂的效果及安全性  

Effect and Safety of Evolocumab Combined with Atorvastatin Calcium in the Treatment of Coronary Heart Disease Complicated with Hyperlipidemia

作　　者：王本军[1] 王高彪 付中华[2] 陈丰毅 WANG Benjun;WANG Gaobiao;FU Zhonghua;CHEN Fengyi(Department of Pharmacy,Zhengzhou Seventh People's Hospital,Zhengzhou 450016,China;Department of Pharmacy,He'nan Provincial People's Hospital,Zhengzhou 450003,China;Department of Cardiology,Zhengzhou Seventh People's Hospital,Zhengzhou 450016,China)

机构地区：[1]郑州市第七人民医院药学部,河南郑州450016 [2]河南省人民医院药学部,河南郑州450003 [3]郑州市第七人民医院心内科,河南郑州450016

出　　处：《临床医学工程》2024年第4期477-478,共2页Clinical Medicine & Engineering

摘　　要：目的探讨依洛尤单抗联合阿托伐他汀钙治疗CHD合并高血脂的效果及安全性。方法102例CHD合并高血脂患者随机分为对照组(阿托伐他汀钙)和观察组(依洛尤单抗+阿托伐他汀钙),比较两组的疗效和不良反应。结果治疗后,观察组的TG、TC、LDL-C、ApoB水平均低于对照组,LDL-C达标率高于对照组(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论依洛尤单抗联合阿托伐他汀钙治疗CHD合并高血脂可下调患者的血脂水平,安全性尚可。Objective To explore the effect and safety of evolocumab combined with atorvastatin calcium in the treatment of CHD complicated with hyperlipidemia.Methods 102 patients with CHD complicated with hyperlipidemia were randomly divided into the control group(atorvastatin calcium)and the observation group(evolocumab+atorvastatin calcium).The eficacy and adverse reactions were compared between the two groups.Results After treatment,the levels of TG,TC,LDL-C,and ApoB in the observation group were lower than those in the control group,and the LDL-C compliance rate was higher than that in the control group(P<0.05).No significant difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Evolocumab combined with atorvastatin calcium in the treatment of CHD complicated with hyperlipidemia can lower patients'blood lipid levels,and the safety is still acceptable.

关 键 词：依洛尤单抗 阿托伐他汀钙 CHD 高血脂 

分 类 号：R541.4[医药卫生—心血管疾病]